What challenges exist in targeting PIK3CA mutations?
Despite the potential of targeting PIK3CA mutations, several challenges remain. Resistance to PI3K inhibitors can develop, often due to compensatory activation of parallel signaling pathways or secondary mutations. Additionally, the toxicity profile of PI3K inhibitors can limit their clinical use. Ongoing research is focused on overcoming these challenges through combination therapies and the development of more selective and potent inhibitors.
